A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma
Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
FIREFLY-1 is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of
oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with
recurrent or progressive low-grade glioma harboring a known BRAF alteration.